There was no statistically significant difference in the incidence of all-grade hepatitis (P = 0.761) or HBV-related hepatitis (P = 0.1) between patients with anti-PD-1 monotherapy or combination therapy. This evidence concerns the gene PDCD1 and hepatitis A virus infection.